Richard Roman, MD
Gastroenterology · Englewood, CONPI 1972616399
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (57.3%), food and beverage and education — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Olympus America Inc. at 57.3% of the total. Reporting peaked in 2023 at $10,967 and has fallen 89.1% since, to $1,200 in 2025. Among gastroenterology clinicians in CO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 315 payments — averaging $52.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus America Inc.$9K
- AbbVie$3K
- Takeda Pharmaceuticals U.S.A., Inc.$823
- Johnson & Johnson$681
- Gilead$473
- Lilly USA, LLC$416
- plus $2K from 25 others
What the payments were for
- Food & beverage$6,99243%
- Education$310%
- Other$9,42057%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus America Inc. | 2 | $9,420 |
| AbbVie(2 entities) | 115 | $2,646 |
| Takeda Pharmaceuticals U.S.A., Inc. | 32 | $823 |
| Johnson & Johnson(3 entities) | 17 | $681 |
| Gilead | 23 | $473 |
| Lilly USA, LLC | 13 | $416 |
| Bristol Myers Squibb | 24 | $393 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $367 |
| Pfizer | 15 | $241 |
| Intercept Pharmaceuticals, Inc. | 12 | $184 |
| Regeneron Healthcare Solutions, Inc. | 5 | $96 |
| Organon | 6 | $83 |
| Ironwood Pharmaceuticals, Inc | 4 | $73 |
| Ferring Pharmaceuticals Inc. | 5 | $73 |
| Axonics, Inc. | 1 | $54 |
| Amgen | 2 | $44 |
| Ipsen Biopharmaceuticals, Inc | 2 | $38 |
| Merck | 2 | $37 |
| Mirum Pharmaceuticals, Inc. | 2 | $36 |
| Sanofi | 2 | $34 |
| QOL Medical, LLC | 2 | $33 |
| Novo Nordisk | 2 | $32 |
| Ardelyx, Inc. | 1 | $25 |
| Madrigal Pharmaceuticals | 1 | $22 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Orphalan Inc | 1 | $15 |
| Aimmune Therapeutics, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EVIS EXERA lll COLONOVIDEOSCOPE$9,419
- EVIS EXERA III GASTROINTESTINAL VIDEOSCOPE$9,419
- Skyrizi$469
- XARELTO$262
- Entyvio$259
- Rinvoq$125
- OMVOH$123
- INVOKANA$123
How this compares
$16,442 in reported general payments places this provider in the 90th percentile of 304 gastroenterology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 36 | $981,271 |
| Humira(Cf) PenAdalimumab | 14 | $90,133 |
| XifaxanRifaximin | 14 | $52,194 |
| CreonLipase/Protease/Amylase | 18 | $51,766 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 123 | $20,229 |
| Mesalamine | 22 | $13,173 |
| Dexlansoprazole DrDexlansoprazole | 13 | $11,171 |
| Budesonide DrBudesonide | 24 | $4,109 |
| Ursodiol | 22 | $3,745 |
| Mesalamine ErMesalamine | 12 | $3,663 |
| SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag | 29 | $3,631 |
| Omeprazole | 151 | $2,773 |
| Esomeprazole Magnesium | 32 | $2,082 |
| Sulfasalazine | 15 | $1,081 |
| Pantoprazole Sodium | 54 | $911 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $681 | $981,27136 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $367 | $52,19414 claims |
| AbbVieCreon | $2,646 | $51,76618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 304 gastroenterology providers in Colorado.
Other gastroenterology in Englewood
- Marcelo KugelmasEnglewood$660K
- Peter McNallyFt Carson$1.1M
- Douglas AdlerColorado Springs$910K
- Mary Ann HuangDenver$408K
- Gareth WeinerThornton$382K
- Matthew NicholsLone Tree$360K
- Nathan SchomakerLone Tree$344K
- Joshua SteinbergNorthglenn$266K
- Rajesh JainLakewood$239K
- Mihir WaghAurora$217K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.